### S6 Table: Sensitivity analysis excluding Serotype 5 from primary case group (All PPV23)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Cases N (%)** | **Controls N (%)** | **Unadjusted Vaccine Effectiveness % (95% CI)** | **Adjusted Vaccine Effectiveness % (95% CI)** | **p-value adjusted analysis** |
| **Number** | 676 | 1640 |  |  |  |
| **Not vaccinated** | 364 (53.9) | 746 (45.5) |  |  |  |
| **Vaccinated** | 312 (46.2) | 894 (54.5) | **28 (14 to 40)** | **26 (7 to 42)\*** | **0.01** |

**S6 Table: Sub-analysis excluding serotype 5 from the primary analysis group (all PPV23 serotypes).** Adjusted for age, gender, receipt of seasonal flu vaccination and presence or absence of the following risk factors: malignancy, cardiac failure, cerebrovascular disease, chronic renal disease, chronic liver disease, diabetes, ischaemic heart disease, COPD, other chronic cardiac disease, other chronic lung disease, hypertension, alcohol dependence and immunosuppression. ^Adjusted for age, gender, receipt of seasonal flu vaccination